The neuroendocrine and metabolic effects of oestrogens

Phase 4

Recruiting

• Conditions: euroendocrine regulation of GH secretion by oestrogens; Metabolic effects of oestrogens; Neuroendocrine regulation of GH secretion by oestrogens; Metabolic and Endocrine - Normal metabolism and endocrine development and function

• Registration Number: ACTRN12611001093976
• Lead Sponsor: Garvan Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Healthy postmenopausal women and men the same age
BMI <25 kg/m2

Exclusion Criteria

History of liver, kidney diseases, cancer, diabetes, endocrine disorders, that are likely to interfere with the metabolism or excretion of the test medication.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Whole body fatty acid metabolism assessed by palmitate turnover technique.[Assessed after each 2 week intervention period, i.e. three times in women and twice in men.];Liver fatty acid metabolism, assessed by VLDL measurements using leucine turnover technique.[Assessed after each 2 week intervention period, i.e. three times in women and twice in men.];GH secretion, assessed by arginine stimulation test[Assessed after each 2 week intervention period, i.e. three times in women and twice in men.]

Secondary Outcome Measures

Name	Time	Method
Resting energy expenditure, assessed by indirect calorimetry[Assessed after each 2 week intervention period, i.e. three times in women and twice in men.];Fat oxidation, assessed by indirect calorimetry[Assessed after each 2 week intervention period, i.e. three times in women and twice in men.]